Zobrazeno 1 - 10
of 219
pro vyhledávání: '"Mian Xi"'
Autor:
Ruixi Wang, Yihong Ling, Baoqing Chen, Yujia Zhu, Yonghong Hu, Mengzhong Liu, Yadi Yang, Li Zhang, Yingxin Lv, Shiliang Liu, Qiaoqiao Li, Mian Xi
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102806- (2024)
Summary: Background: In the EC-CRT-001 phase II study, the combination of toripalimab (an anti-programmed death-1 antibody) and definitive chemoradiotherapy (CRT) has shown promising efficacy in patients with locally advanced oesophageal squamous cel
Externí odkaz:
https://doaj.org/article/5abb1b5ed4e046c99cc4e51b1298e8f3
Autor:
Baoqing Chen, Shiliang Liu, Yujia Zhu, Ruixi Wang, Xingyuan Cheng, Biqi Chen, Mihnea P. Dragomir, Yaru Zhang, Yonghong Hu, Mengzhong Liu, Qiaoqiao Li, Hong Yang, Mian Xi
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract The combination of toripalimab (an anti-PD-1 antibody) with definitive chemoradiotherapy (CRT) demonstrated encouraging efficacy against locally advanced esophageal squamous cell carcinoma (ESCC) in the EC-CRT-001 phase II trial (NCT04005170
Externí odkaz:
https://doaj.org/article/5208618c38c443d3b5493d7559fed793
Publikováno v:
Radiation Oncology, Vol 18, Iss 1, Pp 1-14 (2023)
Abstract Background Definitive radiotherapy plus concurrent chemotherapy has been a standard treatment for esophagus patients who are unfit to undergo surgery. However, there are a variety of concurrent chemotherapy regimens with varying efficacy. In
Externí odkaz:
https://doaj.org/article/a2ebb54ab3994a21a4734a9ca630d8cf
Autor:
Hui Jiang, Qiaoqiao Li, Baoqing Chen, Mian Xi, Kanjiebubi Makelike, Shiliang Liu, Yonghong Hu, Yujia Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 15187-15198 (2023)
Abstract Background This phase I study aimed to assess the safety, dose‐limiting toxicity (DLT), maximum tolerated dose (MTD) and preliminary effect of nanoparticle albumin‐bound (nab)‐paclitaxel in combination with concurrent chemoradiotherapy
Externí odkaz:
https://doaj.org/article/4fe0fa39b65d495c92d2f8902825346e
Autor:
XinLei Ai, PengXin Zhang, XinMin Xie, Bo Qiu, YuJia Zhu, Lei Zhao, Mian Xi, YingJia Wu, SuPing Guo, JinYu Guo, FangJie Liu, DaQuan Wang, NaiBin Chen, QianWen He, YongHong Hu, MengZhong Liu, ZhaoXia Ding, Hui Liu
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 15000-15010 (2023)
Abstract Background We launched a single‐arm phase II study to determine the efficacy and cost‐effectiveness of percutaneous endoscopic gastrostomy (PEG) before concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcino
Externí odkaz:
https://doaj.org/article/970b0330eaa94d80aaf1a5247966c3b1
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Background Esophageal squamous cell carcinoma (ESCC) is the most common esophageal malignancy, and RNA methylation has been reported to be involved in the tumorigenesis of ESCC. However, no study has explored methylation modifications in m1A
Externí odkaz:
https://doaj.org/article/ae5efcf2b5294ba5ad9a0ed0c8f276df
Autor:
Rui Chen, Qianwen Liu, Qiaoqiao Li, Yujia Zhu, Lei Zhao, Shiliang Liu, Baoqing Chen, Mengzhong Liu, Yonghong Hu, Ting Lin, Jibin Li, Jiyang Chen, Yingxin Lv, Jianhua Fu, Mian Xi, Hong Yang
Publikováno v:
EClinicalMedicine, Vol 62, Iss , Pp 102118- (2023)
Summary: Background: To evaluate the efficacy and safety of toripalimab combined with neoadjuvant chemoradiotherapy (NCRT) for locally advanced esophageal squamous cell carcinoma (ESCC). Methods: In this single arm, phase II trial, 44 ESCC patients w
Externí odkaz:
https://doaj.org/article/521bf24d17c141f8a2da428e4bf25a53
Autor:
Yu‐Xian Yang, Yu‐Zhen Zheng, Tian‐Tian Gao, Shi‐Liang Liu, Mian Xi, Meng‐Zhong Liu, Jun‐Ye Wang, Shu‐Nan Qi, Yong Yang, Lei Zhao
Publikováno v:
Cancer Medicine, Vol 11, Iss 20, Pp 3751-3760 (2022)
Abstract Background Despite 3‐year survival being used as a primary endpoint in some randomized controlled trials (RCTs), limited evidence supports the use of intermediate endpoints to evaluate the effect of new therapies in esophageal squamous cel
Externí odkaz:
https://doaj.org/article/979589db026b46739a158bf662fd954b
Autor:
Tian-Tian Gao, Jia-Hui Shan, Yu-Xian Yang, Ze-Wei Zhang, Shi-Liang Liu, Mian Xi, Meng-Zhong Liu, Lei Zhao
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background The study aimed to compare efficacy and safety of various immune checkpoint inhibitors for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). Methods We searched Medline, Web of Science, Cochrane Centr
Externí odkaz:
https://doaj.org/article/17e5ead2b1794e5c9cc0ef59acf225dd
Autor:
Yuxian Yang, Shiliang Liu, Chunxia Xie, Qiaoqiao Li, Tiantian Gao, Mengzhong Liu, Mian Xi, Lei Zhao
Publikováno v:
Biomedical Journal, Vol 46, Iss 2, Pp 100528- (2023)
Background: The molecular mechanisms of esophageal squamous cell carcinoma (ESCC) remain poorly understood. Transmembrane emp24 trafficking protein 3 (TMED3) acts as an oncogene or tumor suppressor gene in different cancers. Our study was to explore
Externí odkaz:
https://doaj.org/article/870be0e175ee4cb9b44453ddfb4c4839